Tempest Therapeutics Stock News

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both t

Tempest Therapeutics Inc (TPST) shares closed 2.1% lower than its previous 52 week low, giving the company a market cap of $29M. The stock is currently down 20.5% year-to-date, down 84.5% over the past 12 months, and down 82.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 39.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.6% lower than its 5-day moving average, 23.2% lower than its 20-day moving average, and 61.6% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 8409.1% The company's stock price performance over the past 12 months lags the peer average by 433.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Tempest Therapeutics Inc (TPST) shares closed today at 1.1% above its 52 week low of $4.39, giving the company a market cap of $31M. The stock is currently down 14.6% year-to-date, down 81.9% over the past 12 months, and down 82.7% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Trading volume this week was 75.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 911.1% The company's stock price performance over the past 12 months lags the peer average by 390.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Tempest Therapeutics Inc (TPST) shares closed 2.8% lower than its previous 52 week low, giving the company a market cap of $37M. The stock is currently down 83.0% year-to-date, down 83.1% over the past 12 months, and down 73.6% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 91.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1139.2% The company's stock price performance over the past 12 months lags the peer average by 980.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

H.C. Wainwright has initiated coverage of Tempest Therapeutics Inc (NASDAQ: TPST) with a Buy rating and $51 price target, seeing an upside potential of over 100%.  A strategic portfolio of target

Shares of the South San Francisco-based micro-cap biopharma Tempest Therapeutics Inc. (NASDAQ: TPST) were soaring Monday for a second consecutive trading session on above-average volume. Tempest's W

Mer Telemanagement (MTSL) stock is heading higher on Monday despite a lack of news from the company and heavy trading of shares. The post MTSL Stock: 16 Things to Know About Penny Stock Mer Telemanage

Tempest Therapeutics (TPST) stock is rocketing higher on Monday and reaching new highs since its merger with Millendo Therapeutics. The post TPST Stock: 13 Things to Know About Tempest Therapeutics as

The stock price of Tempest Therapeutics, Inc. (Nasdaq: TPST) increased by over 120% pre-market. This is why it happened.

The stock price of Tempest Therapeutics, Inc. (Nasdaq: TPST) increased by over 76% intraday. This is why it happened.

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that comb

SOUTH SAN FRANCISCO, July 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics t